Biogen Call and Put Volume: 30-Day Overview Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and ...

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology ...

Panasonic has rung the changes on this second edition of its full-frame flagship. The Lumix S1R II improves upon the original S1R in every key area, battery life excepted. For me, the most ...

Highlights,Truist Financial Corp adjusted its holdings in Biogen Inc., reducing its stake during the fourth quarter.,Multiple institutional investors modified their positions, contributing to overall ...

Bipolar II disorder is a mental health condition that involves at least one depressive episode and at least one period of elevated mood, called hypomania. Bipolar II disorder causes intense ...

The tomb of Pharaoh Thutmose II is the first royal crypt discovered in recent years, and scientists have new powerful tools to analyze it. Egypt's Valley of the Kings is part of a massive ...

A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side ...

Baseball is officially back and the journey to the big show continues for a pair of West Virginia products who are in the St. Louis Cardinals's system - JJ Wetherholt and Victor Scott II.

A British archaeologist believes his team may have found a second tomb in Egypt belonging to King Thutmose II. The potential find comes just days after Piers Litherland announced the discovery of ...

Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...